Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study

Depression is frequent in Parkinson’s disease (PD) patients, but the evidence for many antidepressant agents to treat it in PD is insufficient. The aim of the present prospective open-label single-arm study (VOPARK, an open-label study of the effectiveness and safety of VOrtioxetine in PARKinson’s d...

Full description

Bibliographic Details
Main Authors: Diego Santos García, Maria Gema Alonso Losada, Icíar Cimas Hernando, Iria Cabo López, Rosa Yáñez Baña, Ruben Alonso Redondo, Jose Manuel Paz González, Carlos Cores Bartolomé, Maria José Feal Painceiras, Maria Cristina Íñiguez Alvarado, Carmen Labandeira, Iago García Díaz
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Brain Sciences
Subjects:
depression
effectiveness
open-label study
Parkinson’s disease
vortioxetine
Online Access:https://www.mdpi.com/2076-3425/12/11/1466

Similar Items

Similar Items